3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1
1
Status
Terminated
1
Active not recruiting
1
Sponsor Class
OTHER
2
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Prostatic Neoplasms
20
Prostate Carcinoma Metastatic to the Bone
2
Metastatic Castration-resistant Prostate Cancer
2
Thyroid Neoplasms
1
Prostate Cancer Metastatic to Bone
1
Prostate Adenocarcinoma
1
Pain
1
Neoplasm Metastasis
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Lung Neoplasms
1
Fatigue
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Bony Metastases From Castrate Refractory Prostate Cancer
1
Advanced Prostate Cancer
1
Interventions
Docetaxel
4
enzalutamide
3
darolutamide
3
cabazitaxel
3
Pluvicto
3
testosterone 17 beta-cypionate
2
radium Ra 223 dichloride
2
Nivolumab
2
sipuleucel-T
1
rucaparib
1
poly ICLC
1
pamiparib
1
lactitol
1
fludarabine phosphate
1
fludarabine
1
fluciclovine F-18
1
enfortumab vedotin
1
ebastine
1
copanlisib
1
cabozantinib
1
bempegaldesleukin
1
avelumab
1
alovudine
1
abiraterone
1
Standard of Care
1
Single Photon Emission Computed Tomography Computed Tomography
1
Selegiline
1
Radium-223
1
Radiosurgery
1
Radionuclide Imaging
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
OTHER
×
Metastatic Castration-resistant Prostate Cancer
×
radium Ra 223 dichloride
×
Clear all
NCT04109729
2026-06-01
Rad2Nivo
University of Utah
Phase 1
Active not recruiting
39 enrolled
NCT04237584
2022-10-07
ESCALATE
MANA RBM
Phase 3
Terminated
23 enrolled
11 charts